Diabetes: Cholera Toxin Lends A Hand

June 18, 1997

Charles Thivolet (INSERM Unit 449, Molecular Mechanisms of Diabetes, directed by Jean-Paul Riou in Lyon) is developing a new way to prevent diabetes by protecting insulin-producing pancreatic cells through oral insulin administration. In an article published in PNAS, he reports that the action of insulin can be amplified by concomitantly stimulating the immune system with cholera toxin.

Type I diabetes, an autoimmune disease that affects approximately 200 000 people in France, is due to the destruction of insulin-producing B cells in the pancreas by the immune system (cytotoxic lymphocytes). The only treatment is regular insulin injections.

Strategies being developed to fight this disease include B cell protection by a sort of "immune counterattack". Oral insulin administration has a "vaccinal" effect, provoking an immune reaction when it comes into contact with cells of the intestinal mucosa. Activated lymphocytes trigger the production of antiinflammatory cytokines that protect pancreatic B cells. The underlying mechanisms are unclear, but clinical trials of this approach, first tested in mice, are currently underway in the United States and France. One of the main problems is that large quantities of insulin have to be administered by mouth for several years.

Charles Thivolet (INSERM 449, Lyon), in collaboration with Cecil Czerkinsky (Göteborg University, Sweden), has found an original solution to this obstacle by combining insulin with CTB, the non toxic B subunit of cholera toxin. The aim is to amplify the immune reaction and thereby to obtain similar efficacy with a far lower dose of insulin. The work published in PNAS was based on the NOD diabetic mouse model, treated before the onset of diabetes. After fifteen weeks of treatment, only 2 of the 17 animals in the group treated with insulin and CTB had developed diabetes, compared to 7 of the 16 control animals treated with CTB alone. According to Charles Thivolet, these results are similar to those obtained in other studies in which milligram doses of insulin alone were given for several weeks, whereas he administered only micrograms of insulin in a single intake.

Studies will now focus on the mechanisms underlying the action of this insulin-CTB combination before clinical trials are envisaged.

For more information :

A Cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
Proc. Natl. Acad. Sci (PNAS) USA, Vol. 94, pp. 4610-46114, April 28 1997
Isabelle Bergerot*, Corinne Ploix*, Jacob Peterseny, Valérie Moulin*, Carola Rask, Nicole Fabien*, Marianne Lindblad, Anne Mayer*, Cecil Czerkinsky#**, Jan Bolmgren and Charles Thivolet*

* INSERM Unit 499, Faculté Alexis Carrel, Lyon, France y Zymogenetics, Seattle, WA 98102, USA
# INSERM, Edouard Herriot Hospital, Lyon, France
** Department of Medical Microbiology and Immunology, Guldhedsgatan, University of Göteborg, Sweden

French National Institute for Health and Medical Research (INSERM)

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.